Myasthenia gravis (MG) is strongly associated with antibodies to acetylcholine receptor (AChR), whereas the extent of T cell involvement is not settled. The number of cells secreting interferon-gamma (IFN-'y) in response to AChR during 48 h culture of blood mononuclear cells (PBL) may reflect AChR-reactive T cells. Using an immunospot assay, we detected such cells in 23 of 30 patients with MG at a mean number of 1 per 33.333 PBL. AChR-reactive T cells were also found in patients with other neurological diseases (OND) and in healthy subjects but at lower frequencies and numbers. The T cell response to purified protein derivative and to PHA, and also to two major myelin proteins (basic protein and proteolipid protein) did not differ between MG and the two control groups, underlining the specificity ofan augmented T cell reactivity to AChR in MG. Evaluation of the B cell response by enumerating anti-AChR IgG antibody secreting cells revealed such cells in 27 of 28 patients with MG at a mean value of 1 per 14,085 PBL. Cells secreting anti-AChR antibodies of the IgA and IgM isotypes were also detected in MG, but less frequently, at lower numbers, and only in conjunction with IgG antibody secreting cells. Anti-AChR antibody secreting cells were also found among patient with OND and in healthy controls, but at lower frequencies and numbers. These data confirm that AChR is a major target for autoimmune response in MG. (J. Clin. Invest. 1991. 87:2191-2196
Introduction
Myasthenia gravis (MG)' can be considered a prototype for autoimmune disease in the human. Antibodies against the nicotinic acetylcholine receptor (AChR) of the neuromuscular junction are detectable in -85% of the patients with MG (1, 2) . Further evidence for the importance ofanti-AChR antibod-ies in the pathogenesis ofMG include demonstration ofpassive transfer of MG by IgG from patients with MG to mice (3), transient presence of antibodies and muscular weakness in some of the infants of mothers with MG, and beneficial effect of plasmapheresis. The anti-AChR antibodies are assumed to induce the destruction of the AChR, characteristic for MG, thereby causing the abnormal muscular fatigue and other manifestations of MG (4) . The AChRs are pentameric structures consisting of a2, fl, garmma, and 6 subunits (5). Tzartos et al.
have shown that -60% of anti-AChR antibodies found in MG patients' sera are directed to conformational determinants of the two a-subunits which are known as the main immunogenic region (MIR) and localized on the extracellular portion of the AChR (6) . The concept of a MIR of the AChR as the principal stimulus for antibody production in MG has been challenged by others (7) .
The extent ofT cell involvement in MG is less well defined. When testing reactivity to AChR by the T cell proliferation assay employing [3Hlthymidin incorporation, Newsom-Davis and his group have demonstrated a positive response only among 17% of patients with MG, and also in 9% ofthe control patients (8) . AChR-reactive T cell lines have been raised from patients with MG (9) , and evidence has been presented that such cell lines recognize predominantly the a-subunits among the multiple AChR epitopes (10, 1 1), in analogy with the B cell response. In their analysis of T cell proliferative responses to synthetic peptides ofthe human AChR a-chain sequence, Harcourt et al. observed specific responses to peptide 125-143 in 26% of MG patients, but also in 40% of controls including healthy subjects (12) . The authors speculate whether T cell reactivity to AChR may be more widespread than previously suspected, and that such clones may be controlled more effectively in healthy subjects than in MG, or that T cell-reactive peptides 125-143 may not inevitably be pathogenic in humans. Interestingly, however, a section of this peptide 125-143 can induce experimental autoimmune MG in rats (13) .
We have in this study adopted assays to evaluate the T and B cell responses to AChR at the level ofsingle cells. After recognition of relevant antigen on presenting cells, "memory" T cells respond by secretion of cytokines, among them interferon-gamma (IFN-"y) (14) . This phenomenon can be utilized to enumerate specific "memory" T cells among isolated mononuclear cells (15, 16) . For the B cell-plasma cell axis, individual cells secreting specific antibodies of different isotypes can be detected and enumerated in vitro (17, 18) . We have applied these principles to the analysis of mononuclear cells from peripheral blood from patients with MG and controls. We now report that most patients with MG have AChR-reactive T cells and anti-AChR antibody secreting cells in peripheral blood. AChR-specific T and B cells may, however, also occur in other neurological diseases and in healthy subjects but less frequently and at lower numbers compared to MG. Antigens. Preparation of torpedo AChR: Torpedo AChR was purified from frozen electric organs of Torpedo californica (Pacific BioMarine, CA) as described (19) . Briefly, the receptor was isolated by solubilization of membrane fragments in 1% Triton X-100, followed by affinity chromatography on a Naja Naja Siamnesis neurotoxin-Sepharose resin. The bound receptor was eluted with carbamycholine followed by dialysis. The specific activity was 3,000-4,500 pmol a-Bgt aliquots to a final concentration of 10 ug/ml. For each specimen, cells were also applied into wells in which no antigen or lectin was added. PPD was used as positive control antigen. After 48 h of culture at 37°C
and 7% CO2 in humidity, the plates were washed with PBS. 100-;d aliquots of a rabbit polyclonal anti-human IFN-y antiserum (Interferon Sciences, New Brunswick, NJ) diluted 1/500 were added to each well for 4 h at room temperature. After washing, biotinylated anti-rab- 
Results
Autoreactive T cells. After culture of blood mononuclear cells for 48 h and immunoenzyme staining for secreted IFN-,y, redbrown immunospots appeared which were easy to count in a dissection microscope. The number ofprimed T cells responding specifically to an antigen was estimated after subtraction of the value obtained in parallel culture without antigen (Fig. 2) . AChR-reactive T cells determined by secretion ofIFN-'y in the presence of AChR, were detected in 23 of the 30 patients with MG (77%) (Table I; Fig. 2 ). The numbers of AChR-reactive T cells in the 23 positive patients varied between 1 per 8,333 and 1 per 200,000 PBL (mean, 1 per 33,300 PBL for all 30 patients). AChR-reactive T cells were found in the two control groups, but at lower numbers (P < 0.05 and P < 0.001, respectively; cf. Table I ). The diagnoses in the eight OND patients with AChR-reactive T cells were cerebrovascular disease in four patients and Parkinson's disease, head trauma, paresthesia, and rhizopathy in one patient each.
To evaluate the specificity ofthe T cell response in MG, we selected as control antigens PPD and the myelin components MBP and PLP. T cell reactivity to PPD was found at similar frequencies and levels in blood from patients with MG and the two control groups (Table I) . A proportion ofthe MG patients had also autoreactive T cells to MBP and to PLP, but the fre- quencies did not differ from those in the two control groups, nor did the mean values (Table I) . PHA which promotes polyclonal T cell activation and concurrent IFN-y production, induced similar frequencies and mean numbers of IFN-y secreting cells in MG compared with the two control groups (Table I) .
Anti-AChR antibody secreting cells. Cells secreting antiAChR IgG antibodies were detected in peripheral blood from 27 ofthe 28 MG patients examined (Table II; Cells secreting anti-AChR antibodies of the IgA and the IgM isotypes were also found in blood from the patients with MG, but less frequently, at lower numbers ( Fig. 3 ; Table II) AChR antibodies of all three isotypes, 10 (37%) had IgG and IgA, 3 ( 1 %) had IgG and IgM, 6 (22%) had IgG only, and in 1 patient no anti-AChR antibody secreting cells were detectable. One patient was examined for IgG and IgA only, and had both cell types. Anti-AChR antibody secreting cells were not specific for MG. Cells secreting IgG antibodies were found in half of the patients with OND and also in about half of the healthy controls examined. Compared with MG, the numbers were lower in the other neurological disease (OND) patient group (mean, 1 per 66,667 PBL; P < 0.001) and in the healthy controls (mean, 1 per 35,714 PBL; P < 0.05). Similarly, the numbers of antiAChR IgA antibody secreting cells were higher in MG than in OND (P < 0.01) and healthy subjects (P < 0.05), and the numbers of IgM antibody secreting cells were higher in MG than OND (P < 0.05), whereas the difference with healthy controls did not reach significance.
We found a positive correlation (r = 0.56; P < 0.001) between numbers ofanti-AChR IgG antibody secreting cells and AChR-reactive T cells in the 28 MG patients. Also in the controls, there was a similar correlation between these two variables.
T and B cell responses to AChR in thymectomizedpatients. Of the 30 MG patients, 16 had been subjected to thymectomy (Table III) . The mean value of AChR-reactive T cells was higher in the thymectomized group (P < 0.05). Numbers of anti-AChR antibody secreting cells of all three isotypes were also higher in the thymectomized patients.
Immunoglobulin secreting cells. The patients with MG had higher numbers of cells secreting IgG in peripheral blood compared with those with OND (P < 0.05) or the healthy subjects (P < 0.001). For numbers of IgA and IgM secreting cells, no differences were registered between the group (Table IV) .
Discussion
We have presented evidence that a majority of patients with MG have AChR-reactive T cells in peripheral blood. The high numbers of AChR-reactive T cells in MG patients did not reflect a generally increased capacity to produce IFN-,y in response to antigen or lectin in MG, because the numbers of T cells responding to the common antigen PPD and to the mitogen PHA did not differ significantly in MG compared with OND or healthy subjects. Our finding ofAChR-reactive T cells in patients with OND is in accordance with previous observations by Newsom-Davis and his group of increased T cell proliferation to AChR and to the AChR peptide 125-143 in controls (8, 12) . Whereas these authors detected AChR or peptide reactive T cells at similar frequencies and numbers in patients with MG and controls, we observed that AChR-reactive T cells were more common and present at higher numbers in blood from patients with MG in comparison with patients with OND or healthy subjects. Also, the proliferative response to various AChR sequences has been shown to differ between MG patients and controls (27) .
As control antigens in the T cell assay we used MBP and PLP, i.e., two myelin components of possible relevance in a putative immune pathogenesis of multiple sclerosis. Experimental autoimmune encephalomyelitis (EAE) can be induced by injection of MBP or PLP together with Freund's complete adjuvant (28) (29) (30) , and represents to a certain extent an experimental model of multiple sclerosis. With the same T cell immunospot assay as used in the present study, we have documented that patients with multiple sclerosis have high numbers ofMBP-and PLP-reactive T cells in peripheral blood and especially in cerebrospinal fluid, i.e., in the compartment in the immediate vicinity of the target for a possible immune attack (16) . We have also observed that MBP-and PLP-reactive T cells are not specific for multiple sclerosis but may occur in Anti-AChR antibody secreting cells were present not only in MG but also in the two control groups, although at lower frequencies and numbers. Even though anti-AChR antibodies are generally considered to have pathogenetic relevance in MG, a number of inconsistencies have been described which question the association between anti-AChR antibodies and MG. High antibody levels may thus be demonstrated in MG patients in remission (34) . Newborns to mothers with MG may have no signs ofMG despite high levels ofsuch antibodies (35) . Different diseases such as epilepsy with IgA deficiency (36), primary biliary cirrhosis (37) , and monoclonal gammopathies (38) may be accompanied by anti-AChR antibodies without signs of MG. A pair of identical 47-yr-old twins has been described, one ofthem with MG and the other with high levels of anti-AChR antibodies but no clinical signs of MG (39) . It could be that anti-AChR antibodies are included in the broad repertoire ofnatural antibodies and that an abnormal proliferation of anti-AChR antibody secreting B cell and plasma cell clones, due to a mechanism which remains obscure, is responsible for destruction of AChR in MG. Alternatively, the high production ofanti-AChR antibodies found in MG could represent an immune response secondary to AChR breakdown. Both possibilities are not mutually exclusive.
Our findings of higher numbers of AChR-reactive T and B cells in thymectomized MG patients could be a consequence of the influence on suppressor functions which have been attributed to the thymus (40). However, effects due to differences between thymectomized versus nonoperated patients in type and duration of other forms of immunomodulative measures are not excluded.
In conclusion, we have documented presence of AChRreactive T cells and cells secreting anti-AChR antibodies in most patients with MG. We also observed a strong correlation between B and T cell responses to AChR in the MG patient material. AChR-reactive T and B cells are not specific for MG, but they are detected more frequently in blood from patients with MG, where they are found at higher numbers compared with patients with OND and healthy subjects. Adoption ofthe immunospot assay should facilitate identification of possible immunodominant epitopes which could be active in the immunopathogenesis of MG in the individual patient, and thereby constitute the basis for individually focused immunotherapy.
